Guardant Health (GH) and COTA are collaborating to help biopharmaceutical researchers access COTA's electronic health record data and Guardant's clinicogenomic testing data to speed up the development of new cancer treatments, COTA said Thursday.
The partnership expands COTA's data, particularly in lung, breast, and colorectal cancers, creating a larger, more diverse dataset with significant patient overlap to provide better clinical insights, COTA said.
Price: 31.87, Change: -0.50, Percent Change: -1.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments